Post-exposure prophylaxis for HIV.

[1]  F. Golfier,et al.  [Treatment of sexually transmitted diseases]. , 1998, Contraception, fertilite, sexualite.

[2]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1998, JAMA.

[3]  J. Gerberding,et al.  The Care of Persons with Recent Sexual Exposure to HIV , 1998, Annals of Internal Medicine.

[4]  R. Haug.  Failures of zidovudine postexposure prophylaxis , 1998 .

[5]  R. Haug.  Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. , 1997, MMWR. Morbidity and mortality weekly report.

[6]  D. Cardo,et al.  A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. , 1997, The New England journal of medicine.

[7]  J. Berzofsky,et al.  Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. , 1997, The American journal of medicine.

[8]  C. Ciesielski,et al.  Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. , 1997, The American journal of medicine.

[9]  J. Gerberding,et al.  Zidovudine safety and tolerance among uninfected healthcare workers: a brief update. , 1997, The American journal of medicine.

[10]  R. Black,et al.  Animal studies of prophylaxis. , 1997, The American journal of medicine.

[11]  E. Jochimsen.  Failures of zidovudine postexposure prophylaxis. , 1997, The American journal of medicine.

[12]  J. Gerberding.  Postexposure prophylaxis for human immunodeficiency virus at San Francisco General Hospital. , 1997, American Journal of Medicine.

[13]  J. Gerberding,et al.  Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. , 1997, The New England journal of medicine.

[14]  J L Sullivan,et al.  Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1996, The New England journal of medicine.

[15]  J. Gerberding.  Prophylaxis for Occupational Exposure to HIV , 1996, Annals of Internal Medicine.

[16]  D. Ward,et al.  Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[17]  J. Carlin,et al.  Lifetime cost of human immunodeficiency virus-related health care. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[18]  Douglas D. Richman,et al.  Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel , 1996 .

[19]  J. Sodroski,et al.  Vaginal transmission of chimeric simian/human immunodeficiency viruses in rhesus macaques , 1996, Journal of virology.

[20]  I. de Vincenzi,et al.  Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. European Study Group in Heterosexual Transmission of HIV. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[21]  C. Rietmeijer,et al.  Increasing the use of bleach and condoms among injecting drug users in Denver: outcomes of a targeted, community-level HIV prevention program. , 1996, AIDS.

[22]  A I Spira,et al.  Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques , 1996, The Journal of experimental medicine.

[23]  A. Blauvelt,et al.  The skin as target, vector, and effector organ in human immunodeficiency virus disease. , 1995, The Journal of investigative dermatology.

[24]  J. Gerberding.  Management of occupational exposures to blood-borne viruses. , 1995, The New England journal of medicine.

[25]  J. Gerberding.  Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study. , 1994, The Journal of infectious diseases.

[26]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.

[27]  G. Milman,et al.  Mechanisms of HIV/SIV mucosal transmission. , 1994, AIDS research and human retroviruses.

[28]  M. Sparrow,et al.  Breakage and slippage of condoms in family planning clients. , 1994, Contraception.

[29]  L. Gostin,et al.  HIV testing, counseling, and prophylaxis after sexual assault. , 1994, JAMA.

[30]  G. Satten,et al.  Probability of female-to-male transmission of HIV-1 in Thailand , 1994, The Lancet.

[31]  J. Berzofsky,et al.  HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. , 1994, JAMA.

[32]  W. S. Gogarty.  Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood: Tokars JI, Marcus R, Culver DH, et alAnn Intern Med 118:913–919 Jun 1993 , 1993 .

[33]  J. Martin,et al.  Estimated condom failure and frequency of condom use among gay men. , 1993, American journal of public health.

[34]  M. Steiner,et al.  Can condom users likely to experience condom failure be identified? , 1993, Family planning perspectives.

[35]  J. Tokars,et al.  Surveillance of HIV Infection and Zidovudine Use among Health Care Workers after Occupational Exposure to HIV-Infected Blood , 1993, Annals of Internal Medicine.

[36]  Susan E. Johnson,et al.  Pre- and postexposure chemoprophylaxis: evidence that 3'-azido-3'-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response , 1992, Antimicrobial Agents and Chemotherapy.

[37]  G. Ippolito,et al.  Zidovudine prophylaxis after accidental exposure to HIV: the Italian experience , 1992, AIDS.

[38]  N. Jewell,et al.  Female-to-Male Transmission of Human Immunodeficiency Virus , 1991 .

[39]  R. Ali,et al.  Bloody needles: the volumes of blood transferred in simulations of needlestick injuries and shared use of syringes for injection of intravenous drugs. , 1991, AIDS.

[40]  J. McCune,et al.  Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. , 1991, The Journal of infectious diseases.

[41]  H. Lane,et al.  Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation. , 1990, Annals of internal medicine.

[42]  J. McCune,et al.  Suppression of HIV infection in AZT-treated SCID-hu mice. , 1990, Science.

[43]  D. Ho,et al.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.

[44]  S. Lehrman,et al.  3'-Azido-3'-deoxythymidine in feline leukemia virus-infected cats: a model for therapy and prophylaxis of AIDS. , 1987, Cancer research.

[45]  R. Ruprecht,et al.  Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine , 1986, Nature.

[46]  D. Cardo,et al.  Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood--France, United Kingdom, and United States, January 1988-August 1994. , 1995, MMWR. Morbidity and mortality weekly report.

[47]  C. Miller.  Mucosal transmission of simian immunodeficiency virus. , 1994, Current topics in microbiology and immunology.

[48]  E H Kaplan,et al.  A model-based estimate of HIV infectivity via needle sharing. , 1992, Journal of acquired immune deficiency syndromes.

[49]  J. Wiley,et al.  Heterogeneity in the probability of HIV transmission per sexual contact: the case of male-to-female transmission in penile-vaginal intercourse. , 1989, Statistics in medicine.

[50]  V. DeGruttola,et al.  Infectiousness of HIV between male homosexual partners. , 1989, Journal of clinical epidemiology.

[51]  H. Jaffe,et al.  Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. , 1988, JAMA.